Virendra Tiwari
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Virendra Tiwari has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
Akanksha Mishra
1 shared publication- Bipin Thomas Varghese
Department of Surgical Services, Regional Cancer Centre, Thiruvananthapuram, India
1 shared publication Deepak Janardhan
Regional Cancer Centre
1 shared publicationElizabeth Mathew Iype
Regional Cancer Centre
1 shared publication- Grace Davis
Division of Pharmacology and Pharmaceutical Sciences, University of Missouri-Kansas City (W.S., V.T., G.D., S.J., X.Z.).
1 shared publication - Guokun Zhou
Institute of Pain Medicine and Special Environmental Medicine, Nantong University, Nantong, China
1 shared publication
Latest Publications
- Open Access
- 1 October 2024
- Published by Wolters Kluwer Health in Stroke
- Vol. 55 (10) , 2510-2521
Time-Dependent Potentiation of the PERK Branch of UPR by GPR68 Offers Protection in Brain Ischemia
BACKGROUND: In ischemia, acidosis occurs in/around injured tissue and parallels disease progression. Therefore, targeting an acid-sensitive receptor offers unique advantages in achieving the spatial and temporal specificity required for therapeutic interventions. We previously demonstrated that increased expression of GPR68 (G protein-coupled receptor 68), a proton-sensitive G protein-coupled receptor, mitigates ischemic brain injury. Here, we investigated the mechanism underlying GPR68-dependent protection. METHODS: We performed biochemical and molecular analyses to examine poststroke signaling. We used in vitro brain slice cultures and in vivo mouse transient middle cerebral artery occlusion (tMCAO) models to investigate ischemia-induced injuries. RESULTS: GPR68 deletion reduced PERK (protein kinase R-like ER kinase) expression in mouse brain. Compared with the wild-type mice, the GPR68-/- (knockout) mice exhibited a faster decline in eIF2α (eukaryotic initiation factor-2α) phosphorylation after tMCAO. Ogerin, a positive modulator of GPR68, stimulated eIF2α phosphorylation at 3 to 6 hours after tMCAO, primarily in the ipsilateral brain tissue. Consistent with the changes in eIF2α phosphorylation, Ogerin enhanced tMCAO-induced reduction in protein synthesis in ipsilateral brain tissue. In organotypic cortical slices, Ogerin reduced pH 6 and oxygen-glucose deprivation–induced neurotoxicity. Following tMCAO, intravenous delivery of Ogerin reduced brain infarction in wild-type but not knockout mice. Coapplication of a PERK inhibitor abolished Ogerin-induced protection. Delayed Ogerin delivery at 5 hours after tMCAO remained protective, and Ogerin has a similar protective effect in females. Correlated with these findings, tMCAO induced GPR68 expression at 6 hours, and Ogerin alters post-tMCAO proinflammatory/anti-inflammatory cytokine/chemokine expression profile. CONCLUSIONS: These data demonstrate that GPR68 potentiation leads to neuroprotection, at least in part, through enhancing PERK-eIF2α activation in ischemic tissue but has little impact on healthy tissue.
- 1 October 2024
- Published by Wolters Kluwer Health in Stroke
- Vol. 55 (10) , 2510-2521
Open AccessTime-Dependent Potentiation of the PERK Branch of UPR by GPR68 Offers Protection in Brain Ischemia
BACKGROUND: In ischemia, acidosis occurs in/around injured tissue and parallels disease progression. Therefore, targeting an acid-sensitive receptor offers unique advantages in achieving the spatial and temporal specificity required for therapeutic interventions. We previously demonstrated that increased expression of GPR68 (G protein-coupled receptor 68), a proton-sensitive G protein-coupled receptor, mitigates ischemic brain injury. Here, we investigated the mechanism underlying GPR68-dependent protection. METHODS: We performed biochemical and molecular analyses to examine poststroke signaling. We used in vitro brain slice cultures and in vivo mouse transient middle cerebral artery occlusion (tMCAO) models to investigate ischemia-induced injuries. RESULTS: GPR68 deletion reduced PERK (protein kinase R-like ER kinase) expression in mouse brain. Compared with the wild-type mice, the GPR68-/- (knockout) mice exhibited a faster decline in eIF2α (eukaryotic initiation factor-2α) phosphorylation after tMCAO. Ogerin, a positive modulator of GPR68, stimulated eIF2α phosphorylation at 3 to 6 hours after tMCAO, primarily in the ipsilateral brain tissue. Consistent with the changes in eIF2α phosphorylation, Ogerin enhanced tMCAO-induced reduction in protein synthesis in ipsilateral brain tissue. In organotypic cortical slices, Ogerin reduced pH 6 and oxygen-glucose deprivation–induced neurotoxicity. Following tMCAO, intravenous delivery of Ogerin reduced brain infarction in wild-type but not knockout mice. Coapplication of a PERK inhibitor abolished Ogerin-induced protection. Delayed Ogerin delivery at 5 hours after tMCAO remained protective, and Ogerin has a similar protective effect in females. Correlated with these findings, tMCAO induced GPR68 expression at 6 hours, and Ogerin alters post-tMCAO proinflammatory/anti-inflammatory cytokine/chemokine expression profile. CONCLUSIONS: These data demonstrate that GPR68 potentiation leads to neuroprotection, at least in part, through enhancing PERK-eIF2α activation in ischemic tissue but has little impact on healthy tissue.
- 4 January 2021
- Published by Royal Society of Chemistry (RSC)
- p. 591-607
Chapter 21. Experimental Models to Study Alzheimer's Disease
Despite more than 100 years of discovery, Alzheimer's disease (AD) is still the leading cause of dementia and no curative therapies that may halt its progression are currently available. It is pathologically characterized by the deposition of proteins such as amyloid beta and hyperphosphorylated tau, gliosis and ultimately neuronal death. The currently available treatment approaches only provide symptomatic relief to patients, hence necessitating the introduction of newer animal models to better understand and replicate the pathology of AD. In this chapter we have summarized the popularly used indispensable experimental models of AD and also discussed the advantages and limitations of these models in screening novel therapies for this disease. Alzheimer's disease (AD) is the most common aging-associated neurodegenerative disorder with a complex pathology and multifactorial etiology. A progressive decline in cognitive functions and the accumulation of extracellular β-amyloid plaques and intracellular neurofibrillary tangles in the brain are the characteristic features of this disease. A WHO report estimated that the worldwide population affected with AD ranged between 27–36 million in 2016. Experimental models of AD are important in providing a detailed understanding of the pathogenesis and to screen novel therapeutic approaches. A perfect model is crucial to replicate the symptoms in a sequential manner similar to the disease pathology in humans. Herein, we have summarized the pathological features of various experimental models of AD being globally pursued by researchers.
- 4 January 2021
- Published by Royal Society of Chemistry (RSC)
- p. 591-607
Chapter 21. Experimental Models to Study Alzheimer's Disease
Despite more than 100 years of discovery, Alzheimer's disease (AD) is still the leading cause of dementia and no curative therapies that may halt its progression are currently available. It is pathologically characterized by the deposition of proteins such as amyloid beta and hyperphosphorylated tau, gliosis and ultimately neuronal death. The currently available treatment approaches only provide symptomatic relief to patients, hence necessitating the introduction of newer animal models to better understand and replicate the pathology of AD. In this chapter we have summarized the popularly used indispensable experimental models of AD and also discussed the advantages and limitations of these models in screening novel therapies for this disease. Alzheimer's disease (AD) is the most common aging-associated neurodegenerative disorder with a complex pathology and multifactorial etiology. A progressive decline in cognitive functions and the accumulation of extracellular β-amyloid plaques and intracellular neurofibrillary tangles in the brain are the characteristic features of this disease. A WHO report estimated that the worldwide population affected with AD ranged between 27–36 million in 2016. Experimental models of AD are important in providing a detailed understanding of the pathogenesis and to screen novel therapeutic approaches. A perfect model is crucial to replicate the symptoms in a sequential manner similar to the disease pathology in humans. Herein, we have summarized the pathological features of various experimental models of AD being globally pursued by researchers.
- Open Access
- 30 June 2018
- Published by Springer Nature in Indian Journal of Surgical Oncology
- Vol. 9 (3) , 407-410
Prospective Evaluation of Surgical Outcome After Transoral CO2 Laser Resection of Potentially Malignant and Early Oral Malignancy
A prospective observational study was done at the Regional Cancer Centre, Thiruvananthapuram, a tertiary referral center for cancer care in India with an aim to assess the surgical outcomes of CO2 laser resection of oral lesions in terms of operative time, blood loss, hospital stay, postoperative pain, time to re-epithelization, pathological margins achieved and the postoperative scar. The excision was performed in 30 patients with a diagnosis of either potentially malignant lesions (leucoplakia, erythroplakia) or early cancers, i.e., carcinoma in situ or T1/T2 squamous cell carcinoma of the anterior oral cavity (tongue, buccal mucosa), adhering to standard oncological principles, and the resultant defect was left for secondary healing.
- 30 June 2018
- Published by Springer Nature in Indian Journal of Surgical Oncology
- Vol. 9 (3) , 407-410
Open AccessProspective Evaluation of Surgical Outcome After Transoral CO2 Laser Resection of Potentially Malignant and Early Oral Malignancy
A prospective observational study was done at the Regional Cancer Centre, Thiruvananthapuram, a tertiary referral center for cancer care in India with an aim to assess the surgical outcomes of CO2 laser resection of oral lesions in terms of operative time, blood loss, hospital stay, postoperative pain, time to re-epithelization, pathological margins achieved and the postoperative scar. The excision was performed in 30 patients with a diagnosis of either potentially malignant lesions (leucoplakia, erythroplakia) or early cancers, i.e., carcinoma in situ or T1/T2 squamous cell carcinoma of the anterior oral cavity (tongue, buccal mucosa), adhering to standard oncological principles, and the resultant defect was left for secondary healing.